# Calix, Inc: financial statements, quarterly

CALX · NYSE · CIK 1406666 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/calx.md) · [Financials](/companies/calx/financials.md) · [Filings](/companies/calx/filings.md) · [Insiders](/companies/calx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/calx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [264](/filings/0001406666-24-000039.md) | [265 d](/filings/0001406666-26-000005.md) | [226](/filings/0001406666-25-000016.md) | [198](/filings/0001406666-25-000035.md) | [201](/filings/0001406666-25-000045.md) | [206 d](/filings/0001406666-26-000005.md) | [220](/filings/0001406666-26-000019.md) | [242](/filings/0001406666-26-000034.md) | [265](/filings/0001406666-25-000045.md) | [272 d](/filings/0001406666-26-000005.md) | [280](/filings/0001406666-26-000019.md) | [293](/filings/0001406666-26-000034.md) |
| Cost of revenue | $m | [123](/filings/0001406666-24-000039.md) | [151 d](/filings/0001406666-26-000005.md) | [104](/filings/0001406666-25-000016.md) | [90.5](/filings/0001406666-25-000035.md) | [90.9](/filings/0001406666-25-000045.md) | [92.8 d](/filings/0001406666-26-000005.md) | [97.5](/filings/0001406666-26-000019.md) | [106](/filings/0001406666-26-000034.md) | [113](/filings/0001406666-25-000045.md) | [115 d](/filings/0001406666-26-000005.md) | [121](/filings/0001406666-26-000019.md) | [133](/filings/0001406666-26-000034.md) |
| Gross profit | $m | [141](/filings/0001406666-24-000039.md) | [113 d](/filings/0001406666-26-000005.md) | [123](/filings/0001406666-25-000016.md) | [108](/filings/0001406666-25-000035.md) | [110](/filings/0001406666-25-000045.md) | [113 d](/filings/0001406666-26-000005.md) | [123](/filings/0001406666-26-000019.md) | [136](/filings/0001406666-26-000034.md) | [152](/filings/0001406666-25-000045.md) | [157 d](/filings/0001406666-26-000005.md) | [159](/filings/0001406666-26-000019.md) | [160](/filings/0001406666-26-000034.md) |
| Research and development | $m | [47.0](/filings/0001406666-24-000039.md) | [42.3 d](/filings/0001406666-26-000005.md) | [44.4](/filings/0001406666-25-000016.md) | [44.1](/filings/0001406666-25-000035.md) | [45.5](/filings/0001406666-25-000045.md) | [45.9 d](/filings/0001406666-26-000005.md) | [44.0](/filings/0001406666-26-000019.md) | [45.8](/filings/0001406666-26-000034.md) | [47.1](/filings/0001406666-25-000045.md) | [53.5 d](/filings/0001406666-26-000005.md) | [54.6](/filings/0001406666-26-000019.md) | [52.8](/filings/0001406666-26-000034.md) |
| Operating income | $m | [15.9](/filings/0001406666-24-000039.md) | [(12.1) d](/filings/0001406666-26-000005.md) | [(2.0)](/filings/0001406666-25-000016.md) | [(11.4)](/filings/0001406666-25-000035.md) | [(10.9)](/filings/0001406666-25-000045.md) | [(18.8) d](/filings/0001406666-26-000005.md) | [(6.1)](/filings/0001406666-26-000019.md) | [0.4](/filings/0001406666-26-000034.md) | [17.4](/filings/0001406666-25-000045.md) | [9.3 d](/filings/0001406666-26-000005.md) | [12.7](/filings/0001406666-26-000019.md) | [21.8](/filings/0001406666-26-000034.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.2](/filings/0001406666-24-000039.md) | [(2.4) d](/filings/0001406666-26-000005.md) | [0.4](/filings/0001406666-25-000016.md) | [(0.7)](/filings/0001406666-25-000035.md) | [(3.8)](/filings/0001406666-25-000045.md) | [2.3 d](/filings/0001406666-26-000005.md) | [1.8](/filings/0001406666-26-000019.md) | [3.6](/filings/0001406666-26-000034.md) | [4.7](/filings/0001406666-25-000045.md) | [6.2 d](/filings/0001406666-26-000005.md) | [4.0](/filings/0001406666-26-000019.md) | [6.5](/filings/0001406666-26-000034.md) |
| Net income | $m | [17.0](/filings/0001406666-24-000039.md) | [(6.6) d](/filings/0001406666-26-000005.md) | [0.1](/filings/0001406666-25-000016.md) | [(8.0)](/filings/0001406666-25-000035.md) | [(4.0)](/filings/0001406666-25-000045.md) | [(17.9) d](/filings/0001406666-26-000005.md) | [(4.8)](/filings/0001406666-26-000019.md) | [(0.2)](/filings/0001406666-26-000034.md) | [15.7](/filings/0001406666-25-000045.md) | [7.2 d](/filings/0001406666-26-000005.md) | [11.2](/filings/0001406666-26-000019.md) | [17.1](/filings/0001406666-26-000034.md) |
| Diluted EPS | $ per share | [0.24](/filings/0001406666-24-000039.md) | not reported | [0.00](/filings/0001406666-25-000016.md) | [(0.12)](/filings/0001406666-25-000035.md) | [(0.06)](/filings/0001406666-25-000045.md) | not reported | [(0.07)](/filings/0001406666-26-000019.md) | [0.00](/filings/0001406666-26-000034.md) | [0.22](/filings/0001406666-25-000045.md) | not reported | [0.16](/filings/0001406666-26-000019.md) | [0.26](/filings/0001406666-26-000034.md) |
| Basic EPS | $ per share | [0.26](/filings/0001406666-24-000039.md) | not reported | [0.00](/filings/0001406666-25-000016.md) | [(0.12)](/filings/0001406666-25-000035.md) | [(0.06)](/filings/0001406666-25-000045.md) | not reported | [(0.07)](/filings/0001406666-26-000019.md) | [0.00](/filings/0001406666-26-000034.md) | [0.24](/filings/0001406666-25-000045.md) | not reported | [0.17](/filings/0001406666-26-000019.md) | [0.27](/filings/0001406666-26-000034.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [136](/filings/0001406666-23-000040.md) | [63.4](/filings/0001406666-25-000008.md) | [88.4](/filings/0001406666-24-000017.md) | [84.5](/filings/0001406666-24-000030.md) | [62.4](/filings/0001406666-24-000039.md) | [43.2](/filings/0001406666-26-000005.md) | [42.3](/filings/0001406666-25-000016.md) | [76.5](/filings/0001406666-25-000035.md) | [95.0](/filings/0001406666-25-000045.md) | [143](/filings/0001406666-26-000034.md) | [54.6](/filings/0001406666-26-000019.md) | [68.9](/filings/0001406666-26-000034.md) |
| Current assets | $m | [588](/filings/0001406666-23-000040.md) | [598](/filings/0001406666-25-000008.md) | [579](/filings/0001406666-24-000017.md) | [570](/filings/0001406666-24-000030.md) | [585](/filings/0001406666-24-000039.md) | [585](/filings/0001406666-26-000005.md) | [562](/filings/0001406666-25-000016.md) | [562](/filings/0001406666-25-000035.md) | [616](/filings/0001406666-25-000045.md) | [692](/filings/0001406666-26-000034.md) | [587](/filings/0001406666-26-000019.md) | [595](/filings/0001406666-26-000034.md) |
| Total assets | $m | [927](/filings/0001406666-23-000040.md) | [942](/filings/0001406666-25-000008.md) | [923](/filings/0001406666-24-000017.md) | [918](/filings/0001406666-24-000030.md) | [938](/filings/0001406666-24-000039.md) | [939](/filings/0001406666-26-000005.md) | [917](/filings/0001406666-25-000016.md) | [921](/filings/0001406666-25-000035.md) | [976](/filings/0001406666-25-000045.md) | [1,059](/filings/0001406666-26-000034.md) | [951](/filings/0001406666-26-000019.md) | [954](/filings/0001406666-26-000034.md) |
| Current liabilities | $m | [139](/filings/0001406666-23-000040.md) | [188](/filings/0001406666-25-000008.md) | [146](/filings/0001406666-24-000017.md) | [133](/filings/0001406666-24-000030.md) | [130](/filings/0001406666-24-000039.md) | [131](/filings/0001406666-26-000005.md) | [123](/filings/0001406666-25-000016.md) | [124](/filings/0001406666-25-000035.md) | [123](/filings/0001406666-25-000045.md) | [163](/filings/0001406666-26-000034.md) | [178](/filings/0001406666-26-000019.md) | [210](/filings/0001406666-26-000034.md) |
| Total liabilities | $m | [176](/filings/0001406666-23-000040.md) | [223](/filings/0001406666-25-000008.md) | [180](/filings/0001406666-24-000017.md) | [164](/filings/0001406666-24-000030.md) | [159](/filings/0001406666-24-000039.md) | [158](/filings/0001406666-26-000005.md) | [150](/filings/0001406666-25-000016.md) | [149](/filings/0001406666-25-000035.md) | [154](/filings/0001406666-25-000045.md) | [199](/filings/0001406666-26-000034.md) | [213](/filings/0001406666-26-000019.md) | [244](/filings/0001406666-26-000034.md) |
| Shareholders' equity | $m | [751](/filings/0001406666-24-000039.md) | [719](/filings/0001406666-26-000005.md) | [743](/filings/0001406666-25-000035.md) | [754](/filings/0001406666-25-000045.md) | [779](/filings/0001406666-25-000045.md) | [781](/filings/0001406666-26-000034.md) | [767](/filings/0001406666-26-000034.md) | [773](/filings/0001406666-26-000034.md) | [823](/filings/0001406666-25-000045.md) | [859](/filings/0001406666-26-000034.md) | [738](/filings/0001406666-26-000034.md) | [710](/filings/0001406666-26-000034.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [15.8 d](/filings/0001406666-24-000039.md) | [14.9 d](/filings/0001406666-26-000005.md) | [14.7](/filings/0001406666-25-000016.md) | [22.3 d](/filings/0001406666-25-000035.md) | [16.0 d](/filings/0001406666-25-000045.md) | [15.4 d](/filings/0001406666-26-000005.md) | [17.2](/filings/0001406666-26-000019.md) | [39.4 d](/filings/0001406666-26-000034.md) | [32.3 d](/filings/0001406666-25-000045.md) | [46.0 d](/filings/0001406666-26-000005.md) | [14.6](/filings/0001406666-26-000019.md) | [16.5 d](/filings/0001406666-26-000034.md) |
| Capital expenditure | $m | [3.8 d](/filings/0001406666-24-000039.md) | [4.0 d](/filings/0001406666-26-000005.md) | [3.7](/filings/0001406666-25-000016.md) | [6.0 d](/filings/0001406666-25-000035.md) | [3.2 d](/filings/0001406666-25-000045.md) | [5.1 d](/filings/0001406666-26-000005.md) | [4.3](/filings/0001406666-26-000019.md) | [3.7 d](/filings/0001406666-26-000034.md) | [5.6 d](/filings/0001406666-25-000045.md) | [5.8 d](/filings/0001406666-26-000005.md) | [8.1](/filings/0001406666-26-000019.md) | [4.6 d](/filings/0001406666-26-000034.md) |
| Share repurchases | $m | [32.4 d](/filings/0001406666-24-000039.md) | [44.0 d](/filings/0001406666-26-000005.md) | [3.7](/filings/0001406666-25-000016.md) | [0.0 d](/filings/0001406666-25-000035.md) | [0.0 d](/filings/0001406666-25-000045.md) | [7.0 d](/filings/0001406666-26-000005.md) | [40.0](/filings/0001406666-26-000019.md) | [33.6 d](/filings/0001406666-26-000034.md) | [3.5 d](/filings/0001406666-25-000045.md) | [16.6 d](/filings/0001406666-26-000005.md) | [171](/filings/0001406666-26-000019.md) | [69.4 d](/filings/0001406666-26-000034.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [69.2](/filings/0001406666-23-000040.md) | [69.7](/filings/0001406666-24-000017.md) | [69.7](/filings/0001406666-24-000030.md) | [69.6](/filings/0001406666-24-000039.md) | [68.1](/filings/0001406666-25-000016.md) | [65.7](/filings/0001406666-25-000035.md) | [66.1](/filings/0001406666-25-000045.md) | [66.0](/filings/0001406666-26-000019.md) | [64.5](/filings/0001406666-26-000034.md) | [69.8](/filings/0001406666-25-000045.md) | [68.6](/filings/0001406666-26-000019.md) | [65.5](/filings/0001406666-26-000034.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 62,963,989 at 2026-07-13, from the cover of the [10-Q filed 2026-07-21](/filings/0001406666-26-000034.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.